Partial response, no response, or residual symptoms following antidepressant therapy is common in clinical psychiatry. This study evaluated modafinil in patients with major depressive disorder (MDD) who were partial responders to adequate selective serotonin reuptake inhibitor (SSRI) therapy and excessive sleepiness and fatigue.
This retrospective analysis pooled the data of patients (18-65 yrs) who participated in two randomized, double-blind, placebo-controlled studies of modafinil (6-week, flexible-dose study of 100-400 mg/day or 8-week, fixed-dose study of 200 mg/day) plus SSRI therapy. Patients (n=348) met criteria for several residual symptoms (Epworth Sleepiness Scale [ESS] score>or=10; 17-item Hamilton Depression Scale [HAM-D] score between 4 and 25; and Fatigue Severity Scale [FSS] score>or=4).
Compared to placebo, modafinil augmentation rapidly (within 1 week) and significantly improved overall clinical condition (Clinical Global Impression-Improvement), wakefulness (ESS), depressive symptoms (17-item HAM-D), and fatigue (FSS) (p<.01 for all). At final visit, patients receiving modafinil augmentation experienced statistically significant improvements in overall clinical condition, wakefulness, and depressive symptoms. Modafinil was well tolerated in combination with SSRI.
Results of this pooled analysis provide further evidence suggesting that modafinil is an effective and well-tolerated augmentation therapy for partial responders to SSRI therapy, particularly when patients continue to experience fatigue and excessive sleepiness.
"org/10.1016/j.ejphar.2014.10.063i et al., 2006); the dopamine D 2 /D 3 agonist pramipexole is a potentially efficacious treatment strategy in patients that do not respond to standard antidepressant therapies (Cusin et al., 2013); and the wake promoting agent modafinil has also shown some effectiveness in treatment-resistant depression patients that report fatigue and sleepiness (Fava et al., 2007). The wake promoting effects of modafinil are thought to work via binding to the dopamine and norepinephrine transporters, thereby affecting dopaminergic and adrenergic signaling (Wisor, 2013). "
"In addition, modafinil is described as being helpful with residual symptoms such as fatigue and sedation (84, 85). However, the CANMAT guideline has described two meta-analyses of placebo-controlled RCTs that have reported that, despite many advantages, overall negative results (17, 84, 85). "
[Show abstract][Hide abstract] ABSTRACT: This paper aims to introduce, summarize, and emphasize the importance of the 'Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition'. The guideline broadly covers most aspects of the pharmacological treatment of patients in Korea diagnosed with moderate to severe major depression according to the DSM-IV TR. The guideline establishment process involved determining and answering a number of key questions, searching and selecting publications, evaluating recommendations, preparing guideline drafts, undergoing external expert reviews, and obtaining approval. A guideline adaptation process was conducted for the revised edition. The guideline strongly recommends pharmacological treatment considered appropriate to the current clinical situation in Korea, and should be considered helpful when selecting the appropriate pharmacological treatment of patients diagnosed with major depressive disorder. Therefore, the wide distribution of this guideline is recommended.
Journal of Korean Medical Science 04/2014; 29(4):468-484. DOI:10.3346/jkms.2014.29.4.468 · 1.27 Impact Factor
"Many of the agents used in the management of depression were originally designed for other purposes, but also found to produce an antidepressant effect. For example, modafinil is a novel psychostimulant that has demonstrated efficacy as an adjunct to SSRI antidepressant therapy (Fava et al, 2007). Due to its relative lack of drug interactions, modafinil may be a good alternative for elderly patients who are often receiving multiple medications. "
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.